Enhanced levels of double-strand DNA break repair proteins protect ovarian cancer cells against genotoxic stress-induced apoptosis
© Kalra and Bapat; licensee BioMed Central Ltd. 2013
Received: 7 August 2013
Accepted: 14 September 2013
Published: 17 September 2013
Earlier, proteomic profiling of a Serous Ovarian Carcinoma (SeOvCa) progression model in our lab had identified significantly enriched expression of three double-strand break (DSB) -repair proteins viz. RAD50, NPM1, and XRCC5 in transformed cells over pre-transformed, non-tumorigenic cells. Analysis of the functional relevance of enhanced levels of these proteins was explored in transformed ovarian cancer cells.
Expression profiling, validation and quantitation of the DSB-repair proteins at the transcriptional and protein levels were carried out. Further analyses included identification of their localization, distribution and modulation on exposure to Estradiol (E2) and cisplatin. Effects on silencing of each of these under conditions of genomic-stress were studied with respect to apoptosis, alterations in nuclear morphology and DNA fragmentation; besides profiling known mitotic and spindle check-point markers in DSB-repair.
We identified that levels of these DSB-repair proteins were elevated not only in our model, but generally in cancer and are specifically triggered in response to genotoxic stress. Silencing of their expression led to aberrant DSB repair and consequently, p53/p21 mediated apoptosis. Further compromised functionality generated genomic instability.
Present study elucidates a functional relevance of NPM1, RAD50 and XRCC5 DSB-repair proteins towards ensuring survival and evasion of apoptosis during ovarian transformation, emphasizing their contribution and association with disease progression in high-grade SeOvCa.
KeywordsSeOvCa progression model DSB-repair HR and NHEJ pathways Aneuploidy
Expression of numerous markers associated with DNA damage signaling and repair pathways have been reported in malignant cells . It has also been suggested that such proteins are expressed in response to several genotoxic therapies including radiation and chemotherapeutic drugs . DNA double-strand break (DSB) repair, more specifically homologous recombination (HR) mediated repair pathway is reported to be frequently disrupted in solid high-grade serous ovarian adenocarcinoma (SeOvCa) tumors . Overexpression of such DSB-repair associated proteins is assumed to be associated with endogenous replication stress and high frequency of DNA breaks in transformed cells [4, 5], though functional relevance of these markers remained largely uncharacterized during the disease progression.
The basis of the current study is protein expression profiling of SeOvCa progression model that was carried out earlier and identified differential protein patterns . This protein profiling study was carried out using an in vitro model of SeOvCa progression established earlier in our lab [6, 7]. In brief, several single cell clones were isolated from the malignant ascites of a grade IV SeOvCa patient. During subsequent culture, nineteen of these clones underwent spontaneous immortalization. One of these immortal clones viz. A4 with slow-cycling and non-tumorigenic properties, got transformed (passage ~20-25) into an aggressively proliferating clone that exhibited tumorigenic and metastatic capabilities in in vitro assays. This constitutes the SeOvCa progression model system, wherein early immortal A4 cells with non-tumorigenic potential were termed as pre-transformed or A4-P, and transformed A4-P derived tumorigenic and metastatic cells were termed as A4-T (Additional file 1). With distinct cellular phenotype, such isogenic cellular system provided a suitable progression model of two functionally discrete cell types derived from a single clone. Protein profiling of the progression model led to derivation of two groups based on their qualitative and differential expression patterns. Group I comprised of proteins, qualitatively expressed in either A4-P or A4-T (termed as EEx and LEx proteins based on their identification in Early and Late passage A4 cells respectively), while Group II comprised of proteins expressed at quantitatively different levels in each cell types (threshold = > 2, fold change). Categorization of proteins into functional networks provided a clear insight of cellular functionality and major pathways regulating ovarian cell transformation.
Functional annotation of the 34 LEx proteins revealed an association of diverse cellular processes including resistance to apoptosis, energy metabolism, cell proliferation, angiogenesis and invasion and metastases. Broadly these represent some of the classical hallmarks of cancer . One of the progression-associated function was that of DSB-repair in which, three proteins viz. RAD50, NPM1 & XRCC5 were identified as being highly enriched in transformed cells. Around 50% of high grade SeOvCa tumors exhibit aberrant DSB-repair functions and high prevalence of mutations in DSB-repair genes . In exploring the functional relevance associated with disease progression, we focused on these three LEx proteins of DSB-repair pathways. NPM1 has been suggested to involved in the process of DNA repair in UV irradiated cells  while, loss of NPM1 is found to constitutively activate DNA damage response with increased levels of histone H2AX phosphorylation . NPM1 has been recently identified to be recruited by ubiquitin conjugates downstream of RNF8 and RNF168 in HR pathway . RAD50 as a key component of MRN (MRE11, RAD50 & NBS1) complex participates in both DSB repair pathways of HR and non-homologous end-joining (NHEJ), while XRCC5 is one of the key protein involved in NHEJ repair [12–15].
On this background, to elucidate their contribution to disease progression, we characterized the functional involvement of NPM1, RAD50 and XRRC5 DSB-repair proteins in ovarian cancer. Our study demonstrates an approach of transformed cells towards combating DSB-repair, impairment of which leads to apoptosis and genomic instability.
Cell culture, treatments and transfections
Derivation of the A4 progression model of pre-transformed and transformed SeOvCa cells (A4-P and A4-T cells) is described earlier [7, 16]. A4-P cells (between passage numbers 15–17) and A4-T cells (between passage numbers 37–38) were used in the study and cultured stringently to avoid the risk of cross-contamination. The A4-T cells were treated with estradiol (E2; 10 nM) for 48 h and expression analysis of c-Myc, NPM1 and RAD50 was performed. The siRNA pools of negative control, NPM1, RAD50 and XRCC5 (MISSION siRNA; Sigma Aldrich Inc.) were used for generating transient knockdown cells. The A4-T cells were treated with 4 μM cisplatin (Sigma Aldrich Inc.) for 24 h, 48 h time-points and were subsequently used for expression analysis and validation studies. In siRNA transfections, 10 nmol siRNA duplexes were transfected into A4-T cells with Lipofectamine RNAiMax (Invitrogen) according to the manufacturer’s instructions, and cells were analyzed for expression validation after 48 h of transfection. To induce DNA damage and to examine H2AX-γ and NPM1 translocalization, A4-T cells 24 h after transfection were treated with 4 μM cisplatin for 24 h before immunofluorescence analysis. The 4 μM cisplatin treatment for 48 h post 24 h transfection was given to validate protein expression levels of ATM, pATR(Str428), RAD50, NPM1, XRCC5, p53, p21, CDK1, Cyclin D1, Bcl-2 and β-actin.
Semi-quantitative reverse transcription-PCR
Trizol™ reagent (Invitrogen, USA) was used to extract total RNA from cells as per manufacturer’s guidelines . Semi-quantitative reverse transcription-PCR was performed under standard conditions as described earlier  and amplified products were resolved on a 1.5% Agarose gel; β-actin was used as internal control. Gel was run and captured under gel documentation system (Syngene; Cambridge, UK).
Antibodies, immunoblotting and quantitative analysis
Immunoblotting (IB) was performed as described earlier . Primary antibodies were used at following concentrations for IB and IF (immunofluorescence) applications; anti-NPM1 (Sigma #WH0004869M1), 1:4000(IB), 1:150(IF); anti-RAD50 (Sigma #R1653), 1:1000(IB), 1:100(IF); anti-XRCC5 (Ku86, B-1) (Santa Cruz # sc-5280), 1:2000(IB), 1:100(IF); anti-c-Myc (Origene # TA100010), 1:1000; anti-Gamma H2AX (phospho Ser139) (Abcan #ab-11174), 1:2000(IB), 1:100(IF); anti-ATM (H-248) (Santa Cruz #sc-7230), 1:1000; anti-phospho-ATR(Ser428) (Cell Signaling #2853), 1:1000(IB); anti-p53 (DO-1) (Santa Cruz # sc-126), 1:1000(IB), 1:100(IF); anti-p21 (BD #556430), 1:1500; anti-Bcl-2  (Santa Cruz # sc-130308), anti-Cyclin D1 (BD #554180), 1:1000(IB); ant-Cdk-1 (Santa Cruz # sc-53219), 1:1000; anti-α-tubulin (Sigma #T5168), 1:5000(IF); ant-γ-tubulin (Sigma #5192), 1:1000(IF); anti-MAD2 (E-17) (Santa Cruz # sc-31790), 1:100(IF), and anti-BUBR1 (N-20) (Santa Cruz # sc-16193), 1:100(IF). Probing with an anti-β-actin antibody (Clone AC-15) (Sigma # A1978), 1:10,000(IB); served as a loading control. Secondary antibodies linked with horseradish peroxidase (HRP) were used as follows: anti-rabbit (1:1500), anti-mouse (1: 1500) procured from Amersham (Pharmacia Biotech, Little Chalfont, UK). Immunoblots were scanned and densitometry for quantitative analysis was performed using a Syngene Gene Genius™ Gel Documentation System (Syngene; Scientific Laboratory Supplies; #http://www.syngene.com). Protein expression values normalized with β-actin were represented as relative expression in percentage.
Cell cycle and apoptosis assay
Cell cycle analysis of transfected cells was performed with PI (Propidium-Iodide) staining using standard procedure . Sample acquisition and data analysis was performed on FACSCalibur (Becton Dickinson, San Diego, CA, http://www.bdbiosciences.com) using ModFit analytical software. Annexin V–FITC apoptosis assay was performed as described earlier  and acquisitions were made on FACSCanto II (Becton Dickinson); DiVa software (Becton Dickinson) was used for data analysis.
Immunofluorescence staining and In-situ fluorescein cell-death detection (TUNEL) assay
Control siRNA, siNPM1, siRAD50 and siXRCC5 transfected A4-T cells were grown on cover slips for 24 h followed by treatment with cisplatin and E2 for 24-48 h wherever indicated. After treatment, media was decanted and wells washed with 1X PBS buffer. Cells were fixed with 4% paraformaldehyde and were kept for 10 min on ice. Immunofluorescence staining was performed as described earlier  using NPM1, RAD50, XRCC5, H2AX-γ and p53 antibodies; Hoechst was used for nuclear staining. Images were acquired and analyzed on confocal microscope (Carl Zeiss, Jena, Germany). Quantification of intensity of p53 nuclear foci was carried by measuring the expression intensity across nuclei dimension on Leica LAS_AF analysis platform. Intensity of p53 foci was represented on y-axis, while distance or length of nuclei is shown at x-axis. TUNEL Assay was performed as described earlier . Cells with labeling solutions (Roche) were taken as negative control. Cells were washed thrice and stained with Hoechst for nuclear staining. Stained samples were acquired and analyzed on confocal microscope (Leica, Germany).
Control, NPM1, RAD50 and XRCC5 siRNA transfected A4-T cells were grown in 24 well plate and treated with cisplatin (4 μM) and E2 (10 nM) for next 48 h. Upon harvesting, cells were washed twice with chilled 1X phosphate buffer saline (PBS) and then fixed with ice-cold absolute methanol for 20 min at 4°C. Cells were rinsed once with PBS and incubated with Giemsa stain for 30 min at RT. Further, cells were washed twice with 1X PBS and analyzed under Olympus microscopy (Olympus Co., Tokyo, Japan) at 40X magnification.
All experiments were carried out in triplicate; data are expressed as mean ± SEM of three independent experiments. The significance of difference in the mean values was determined using two-tailed Student's t test; wherein p < 0.05 considered significant. ANOVA test was performed to compare protein expression between the groups at a significance level of < 0.05. Student-Bonferroni test was used to evaluate sub-comparisons to error rate.
Transformation-associated DSB Repair proteins are enriched in ovarian cancer
Transformation-associated DSB-repair proteins are responsive to genotoxic stress
Towards investigating the relevance of DSB-repair on genotoxic stress, we induced DSB with 4 μM cisplatin-a genotoxic agent known to form interstrand and intrastrand adducts upon interaction with DNA . The expression of DSB marker i.e. H2AX-γ was significantly upregulated along with the levels of all three DSB repair molecules, though it was much marked for RAD50 and XRCC5 (Figure 2C, 2D). An interesting feature observed was that while the levels of NPM1 were drastically increased on transformation, they were marginally altered on subsequent exposure to genotoxic stress. On profiling its localization at steady-state and under DSB stress, NPM1 was seen to be exported from the nucleolus to the nucleoplasm within 24 h of cisplatin treatment (Figure 2E). The cells treated with cisplatin showed surface granulations and condensed nuclei in comparison to untreated control that indicated onset of cellular stress and apoptosis in a significant cellular fraction (Additional file 4D,E,F). The translocation of NPM1 from the nucleolus to the nucleoplasm may suggest activation and a shift to perform its functional role in DSB-repair.
Impaired DSB-repair and genotoxic stress leads to cellular apoptosis
NPM1 silencing led to significantly elevated XRCC5 levels in these compromised HR DSB-repair cells; likewise, NHEJ compromised cells on XRCC5 silencing exhibited elevated NPM1 levels (Additional file 5B). Such enhanced expression of XRCC5 and NPM1 across alternatively silenced cells indicated prompt activation of respective NHEJ or HR pathways in these impaired cells. In sensitive cells, cisplatin treatment is known to regulate p53 stability and transcriptional activity upon activation of ATM and ATR kinase, while the transient sub-nuclear redistribution of NPM1 may suggest its activation through a direct interaction with p53 independently of ARF [10, 25]. The suggested regulatory cross-talk with p53 prompted us to further profile the protein expression of some key p53-regulatory network molecules activated by ATR phosphorylation (Ser428) or ATM and H2AX-γ expression in cisplatin treated cells (Figure 3B, Additional file 5D). The activated p53 with its down-stream modulator p21 suggested lower Bcl-2 levels in NPM1 silenced cells in comparison to control siRNA transfected cells, though p21 levels appear unaltered throughout the set that may reflect transient stability or a sort half-life of p21 protein. A slightly higher Bcl-2 level in siXRCC5 cells in comparison to siNPM1 and siRAD50 cells may suggest stimulation of the error-free DSB-repair mediated through HR pathway, which may further rescue cells from p53-mediated apoptosis. Lower levels of Cyclin D1 and Cdk1 in DSB-repair protein silenced cells in comparison to control siRNA cells exhibits p53/p21 mediated control over cell cycle progression in RAD50, NPM1 and XRCC5 silenced cells, though individual Cdk-1 levels in siXRCC5 cells were found significantly lower. We observed incidences of nuclear fragmentation in RAD50 and NPM1 silenced cells in comparison to control siRNA transfected cells (Additional file 5E). The consequence of these incidences i.e. cellular apoptosis were quantified through TUNEL assay in the complete treatment set (Figure 3C) wherein, higher levels of nuclear fragmentation in the RAD50 and NPM1 silenced cells in comparison to control siRNA transfected cells corroborate with the above results (Figure 3D).
Compromised HR & NHEJ-repair pathways result in genomic instability in transformed cells
We further analyzed mitotic nuclei to demonstrate the probability of aberrant spindle formation in DSB-repair deficient cells. The α-tubulin and γ-tubulin staining of mitotic nuclei revealed 5–9 fold aberrant mitotic-spindle formation and higher numbers (>2) of centrosomes in DSB-repair deficient cells (Figure 4B). Cyclin E-Cdk2 mediated phosphorylation of NPM1 has been suggested to dissociate its binding from centrosomes at the G1-phase of the cell cycle and permit centrosome duplication prior to cell division . NPM1 silencing thereby could lead to unrestricted centrosome duplication and impaired cell division followed by multinucleation. On the other hand, RAD50 and XRCC5 silencing led to irregular chromosomal segregation generating abnormal mitotic figures. Such association of mitotic irregularities with impaired DSB repair led us to examine genomic content and ploidy levels in the silenced cells under stress. While the former was not significantly altered, the incidence of aneuploidy was enhanced 5–7 fold times in cells with compromised DSB-repair in comparison to the transfected siRNA controls (Figure 4C). Occurrence of mitotic irregularities and analyses of genomic content in RAD50, NPM1 and XRCC5 silenced cells demonstrated gain of genomic instability. Further, MAD2 and BUBR1 levels (upregulations of which are known to be associated with genomic instability) were studied under genotoxic-stress (Additional file 6C). Expressions of MAD2 were found higher in RAD50 and NPM1 silenced cells, while BUBR1 levels were slight high in RAD50 silenced cells. Elevated expression of MAD2 in these silenced cells may suggest progression of genomic instability. Together, the data identifies defective DSB-repair driven genomic instability (GI) that could lead to altered ploidy levels in transformed cells under genomic-stress.
Induction of H2AX-γ in response to genotoxic-stress provided a suitable system to investigate the process of DSB-repair in transformed cells. A nucleolar-nuclear translocation of NPM1 on cisplatin induced genotoxic-stress comprising a swift DSB-repair response in the nucleoplasm was identified. High grade SeOvCa has been suggested to harbor p53 mutation at advanced stage , though it is found limited to 91-96% in serous malignancies [3, 28, 29]. Activation of ATM dependent p53/p21 signaling in compromised DSB repair cells leads to downstream control over Bcl-2, Cdk-1 and Cyclin D1 expression, such mechanistically coordinated process affirms active p53 status in A4-T cells. Presence of stable p21 levels, despite p53 activation justifies transient expression of p21 protein upon DNA damage. RAD50 silencing apparently limits process of DSB repair down-stream of the MRN complex; while activation of NHEJ or HR pathways in NPM1 or XRCC5 silenced cells interestingly demonstrates alternative strategies for DSB-damage repair (Figure 5). Higher frequency of apoptosis in NPM1 silenced cells in comparison to RAD50 and XRCC5 silenced may justify consequence of cumulative shut-down of several functions mediated by NPM1 [25, 26]. Compromised DSB-repair process leads to the mitotic irregularities and multinucleation; wherein unrestricted centrosome duplication in the absence of NPM1 has been reported . Defective repair in NPM1 silenced cells indicates probability of error-prone chromosomal segregation of unrepaired DNA, resulted in generation of aberrant and mutipolar mitotic spindles. Our findings suggest enhanced expression of these three DSB repair molecules is a crucial event during SeOvCa transformation in order to maintain DNA integrity and genomic stability (Figure 5). Conclusively, we demonstrated that silencing of NPM1, RAD50 and XRCC5 in transformed cells led to mitotic irregularities and aneuploidy. Elevated levels of these DSB-markers in transformed cells are essential to compensate the effects of high risk of DSB events in transformed cells. In present study, analysis of the functional relevance of these proteins of DSB-repair extends current understanding of the process of cellular transformation during progression of SeOvCa.
Epithelial ovarian cancer
Serous ovarian adenocarcinoma
Non-homologous end joining
DNA damage repair
Human homolog of Saccharomyces cerevisiae Rad50
X-ray repair cross-complementing 5
Research is funded by the Department of Biotechnology, Government of India, New Delhi to S. A. Bapat (Grant no.BT/PR7186/MED/14/965/2006). RS Kalra received a research fellowship from the Department of Biotechnology, New Delhi. Technical assistance by Mr. Avinash Mali, Mihir Metkar, Manish Kumar and support from the Proteomics, FACS and confocal facilities at NCCS are gratefully acknowledged.
- Zhou BB, Bartek J: Targeting the checkpoint kinases: chemosensitization versus chemoprotection. Nat Rev Cancer 2004, 4: 216–25. 10.1038/nrc1296PubMedView Article
- Kastan MB, Bartek J: Cell-cycle checkpoints and cancer. Nat 2004, 432: 316–323. 10.1038/nature03097View Article
- Berchuk CGARN: Integrated genomic analyses of ovarian carcinoma. Nature 2011, 474: 609–615. 10.1038/nature10166View Article
- Gorgoulis VG, Vassiliou LV, Karakaidos P, Zacharatos P, Kotsinas A, Liloglou T, Venere M, Ditullio RA Jr, Kastrinakis NG, Levy B, Kletsas D, Yoneta A, Herlyn M, Kittas C, Halazonetis TD: Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 2005, 434: 907–913. 10.1038/nature03485PubMedView Article
- Halazonetis TD, Gorgoulis VG, Bartek J: An oncogene-induced DNA damage model for cancer development. Sci 2008, 319: 1352–1355. 10.1126/science.1140735View Article
- Kalra RS, Bapat SA: Expression proteomics predicts loss of RXR-γ during progression of epithelial ovarian cancer. PLoS ONE 2013,8(8):e70398. 10.1371/journal.pone.0070398PubMed CentralPubMedView Article
- Bapat SA, Mali AM, Koppikar CB, Kurrey NK: Stem and progenitor-like cells contribute to the aggressive behavior of human epithelial ovarian cancer. Cancer Res 2005, 65: 3025–3029.PubMed
- Hanahan D, Weinberg RA: Hallmarks of cancer: the next generation. Cell 2011, 144: 646–674. 10.1016/j.cell.2011.02.013PubMedView Article
- Wu MH, Yung BY: UV stimulation of nucleophosmin/B23 expression is an immediate-early gene response induced by damaged DNA. J Biol Chem 2002, 277: 48234–48240. 10.1074/jbc.M206550200PubMedView Article
- Colombo E, Bonetti P, Lazzerini Denchi E, Martinelli P, Zamponi R, Marine JC, Helin K, Falini B, Pelicci PG: Nucleophosmin is required for DNA integrity and p19Arf protein stability. Mol Cell Biol 2005, 25: 8874–8886. 10.1128/MCB.25.20.8874-8886.2005PubMed CentralPubMedView Article
- Koike A, Nishikawa H, Wu W, Okada Y, Venkitaraman AR, Ohta T: Recruitment of phosphorylated NPM1 to sites of DNA damage through RNF8-dependent ubiquitin conjugates. Cancer Res 2010, 70: 6746–6756. 10.1158/0008-5472.CAN-10-0382PubMedView Article
- Franco S, Gostissa M, Zha S, Lombard DB, Murphy MM, Zarrin AA, Yan C, Tepsuporn S, Morales JC, Adams MM, Lou Z, Bassing CH, Manis JP, Chen J, Carpenter PB, Alt FW: H2AX prevents DNA breaks from progressing to chromosome breaks and translocations. Mol Cell 2006,21(2):201–214. 10.1016/j.molcel.2006.01.005PubMedView Article
- Sonoda E, Hochegger H, Saberi A, Taniguchi Y, Takeda S: Differential usage of onhomologous end-joining and homologous recombination in double strand break repair. DNA Repair 2006, 5: 1021–1029. 10.1016/j.dnarep.2006.05.022PubMedView Article
- Hopfner KP, Craig L, Moncalian G, Zinkel RA, Usui T, Owen BA, Karcher A, Henderson B, Bodmer JL, McMurray CT, Carney JP, Petrini JH, Tainer JA: The Rad50 zinc-hook is a structure joining Mre11 complexes in DNA recombination and repair. Nature 2002, 418: 562–566. 10.1038/nature00922PubMedView Article
- Boulton SJ, Jackson SP: Components of the Ku-dependent non-homologous end-joining pathway are involved in telomeric length maintenance and telomeric silencing. EMBO J 1998, 17: 819–828.View Article
- Wani AA, Sharma N, Shouche YS, Bapat SA: Nuclear–mitochondrial genomic profiling reveals a pattern of evolution in epithelial ovarian tumor stem cells. Oncogene 2006, 25: 6336–6344. 10.1038/sj.onc.1209649PubMedView Article
- Ribaudo R, Gilman M, Kingston RE, Choczynski P, Sacchi N: Preparation of RNA from tissues and cells. Curr Protoc Immunol 2001,10(10):11.PubMed
- Kurrey NK, Jalgaonkar SP, Joglekar AV, Ghanate AD, Chaskar PD, Doiphode RY, Bapat SA: Snail and Slug mediate radio- and chemo-resistance by antagonizing p53-mediated apoptosis and acquiring a stem-like phenotype in ovarian cancer cells. Stem Cells 2009, 27: 2059–2068. 10.1002/stem.154PubMedView Article
- Sharma N, Jadhav SP, Bapat SA: CREBBP re-arrangements affect protein function and lead to aberrant neuronal differentiation. Differentiation 2010, 79: 218–231. 10.1016/j.diff.2010.02.001PubMedView Article
- Bapat SA, Krishnan A, Ghanate AD, Kusumbe AP, Kalra RS: Gene expression: protein interaction systems network modeling identifies transformation-associated molecules and pathways in ovarian cancer. Cancer Res 2010, 70: 4809–4819. 10.1158/0008-5472.CAN-10-0447PubMedView Article
- Li Z, Van Calcar S, Qu C, Cavenee WK, Zhang MQ, Ren B: A global transcriptional regulatory role for c-Myc in Burkitt's lymphoma cells. Proc Natl Acad Sci U S A 2003, 8: 164–8169.
- Dubik D, Dembinski TC, Shiu RP: Stimulation of c-myc oncogene expression associated with estrogen-induced proliferation of human breast cancer cells. Cancer Res 1987, 47: 6517–6521.PubMed
- Dubik D, Shiu RP: Transcriptional regulation of c-myc oncogene expression by estrogen in hormone-responsive human breast cancer cells. J Biol Chem 1988, 263: 12705–12708.PubMed
- Eastman A, Barry MA: Interaction of trans-diamminedichloroplatinum(II) with DNA: formation of monofunctional adducts and their reaction with glutathione. Biochem 1987, 26: 3303–3307. 10.1021/bi00386a009View Article
- Colombo E, Marine JC, Danovi D, Falini B, Pelicci PG: Nucleophosmin regulates the stability and transcriptional activity of p53. Nat Cell Biol 2002, 4: 529–533. 10.1038/ncb814PubMedView Article
- Tokuyama Y, Horn HF, Kawamura K, Tarapore P, Fukasawa K: Specific phosphorylation of nucleophosmin on Thr199 by cyclin-dependent kinase 2-cyclin E and its role in centrosome duplication. J Bio Chem 2001, 276: 21529–21537. 10.1074/jbc.M100014200View Article
- Ahmed AA, Etemadmoghadam D, Temple J, Lynch AG, Riad M, Sharma R, Stewart C, Fereday S, Caldas C, Defazio A, Bowtell D, Brenton JD: Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. J Pathol 2010, 221: 49–56. 10.1002/path.2696PubMed CentralPubMedView Article
- Wojnarowicz PM, Oros KK, Quinn MC, Arcand SL, Gambaro K, Madore J, Birch AH, de Ladurantaye M, Rahimi K, Provencher DM, Mes-Masson AM, Greenwood CM, Tonin PN: The genomic landscape of TP53 and p53 annotated high grade ovarian serous carcinomas from a defined founder population associated with patient outcome. PLoS One 2012, 7: e45484. 10.1371/journal.pone.0045484PubMed CentralPubMedView Article
- Kuhn E, Kurman RJ, Vang R, Sehdev AS, Han G, Soslow R, Wang TL, Shih Ie M: TP53 mutations in serous tubal intraepithelial carcinoma and concurrent pelvic high-grade serous carcinoma: evidence supporting the clonal relationship of the two lesions. J Pathol 2012, 226: 421–426. 10.1002/path.3023PubMedView Article
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.